BAVENCIO® Receives Reimbursement Recommendation From pCODR and INESSS for the Maintenance Treatment of Patients With Advanced Bladder Cancer

BAVENCIO (avelumab for injection) has received recommendations to be reimbursed with clinical criteria and conditions

29 Apr 2021 | MISSISSAUGA, ON, Canada

EMD Serono Canada, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Canada ULC are pleased to announce that PrBAVENCIO® (avelumab for injection) has received recommendations to be reimbursed with clinical criteria and conditions, from the pan-Canadian Oncology Drug Review (pCODR) and by the Institut national d'excellence en santé et en services sociaux (INESSS). BAVENCIO is approved by Health Canada for the maintenance treatment of patients with unresectable locally advanced or metastatic urothelial carcinoma (UC), an advanced type of bladder cancer, whose disease has not progressed following first-line platinum-based chemotherapy.

“BAVENCIO addresses an urgent unmet need for patients with metastatic UC and disease that has not progressed on first line platinum-based chemotherapy,” says Dr. Srikala Sridhar, MD MSc FRCPC, Head of the Genitourinary Medical Oncologists of Canada, Associate Professor and Medical Oncologist at the Princess Margaret Cancer Centre. “The reimbursement recommendations by pCODR and INESSS are an important step in getting this treatment to these patients in Canada who need it the most.”

“Urothelial carcinoma patients who are diagnosed at the metastatic stage face a five-year survival rate of five per cent; what they need urgently is access to treatment options with as few challenges as possible,” says Ferg Devins, a survivor of non muscle invasive bladder cancer and Volunteer Board Chair of Bladder Cancer Canada. “The recommendations are welcomed by patients and their loved ones as a way to help manage the outcomes of this difficult disease.”

“Following the Health Canada approval in 2020, we are excited by the pCODR and INESSS milestone recommendations on BAVENCIO” says Manuel Zafra, Managing Director of EMD Serono. “We are proud of what this partnership between EMD Serono and Pfizer Canada can achieve for Canadian UC patients.”
"The recommendation by pCODR and INESSS helps to drive our Alliance’s continued commitment to patients," says Cynthia Di Lullo, Oncology Lead, Pfizer Canada ULC. "We look forward to working with participating jurisdictions across Canada to increase access to BAVENCIO for the treatment of metastatic UC."

The recommendations in full can be accessed at CADTH.ca and INESSS.qc.ca; BAVENCIO is currently under consideration for negotiation by the pan-Canadian Pharmaceutical Alliance (pCPA).

For further information: Smita Devane-Bhan